Pazopanib Hydrochloride CAS 635702-64-6 Purity >99.0% (HPLC) API Factory
Pasokan Produsen kanthi Kemurnian Tinggi lan Kualitas Stabil
Jeneng Kimia: Pazopanib Hydrochloride
CAS: 635702-64-6
Inhibitor reseptor tirosin kinase kanggo perawatan karsinoma sel ginjel lanjut utawa sarkoma jaringan alus sing wis nampa kemoterapi sadurunge.
API Kualitas Tinggi, Produksi Komersial
Jeneng Kimia | Pazopanib Hydrochloride |
sinonim | Pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimetil-2H-indazol-6-yl)(metil)amino]pirimidin-2-yl]amino]-2-metilbenzenesulfonamida Hidroklorida |
Nomer CAS | 635702-64-6 |
Nomer CAT | RF-API93 |
Status Simpenan | Ing Stok, Skala Produksi Nganti Atusan Kilogram |
Formula Molekul | C21H23N7O2S.ClH |
Bobot Molekul | 473.987 |
Kelarutan | DMSO |
Titik Lebur | 300.0~304.0 ℃ |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Wêdakakêna putih nganti rada kuning |
Identifikasi | Spektrum panyerepan inframerah saka sampel tes cocog karo standar |
Sisa ing Ignition | ≤0,50% |
Sembarang Najis Individu | ≤0,30% |
Total Impurities | ≤1,50% |
Logam abot | ≤10ppm |
Kemurnian / Metode Analisis | ≥99,0% (HPLC) |
Test Standar | Standar Perusahaan |
Panggunaan | API, inhibitor reseptor tirosin kinase |
Paket: Botol, tas Aluminium foil, Drum karton, 25kg / Drum, utawa miturut kabutuhan pelanggan.
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya, kelembapan lan infestasi hama.
Pazopanib Hydrochloride (CAS 635702-64-6) minangka inhibitor multi-tirosin kinase saka reseptor faktor pertumbuhan endothelial vaskular (VEGFR) -1, VEGFR-2, VEGFR-3, reseptor faktor pertumbuhan sing diturunake platelet (PDGFR) -α lan - β, fibroblast growth factor receptor (FGFR)-1 lan -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), lan transmembrane glycoprotein receptor tyrosine kinase (cFms).In vitro, pazopanib nyandhet autophosphorylation sing diakibatake ligan saka reseptor VEGFR-2, Kit, lan PDGFR-beta.Ing vivo, pazopanib nyegah fosforilasi VEGFR-2 sing diakibatake VEGF ing paru-paru tikus, angiogenesis ing model tikus, lan tuwuhing sawetara xenograf tumor manungsa ing tikus.Iki disetujoni kanggo karsinoma sel ginjal dening US Food and Drug Administration ing 2009 lan dipasarake kanthi jeneng dagang Votrient dening pabrikan obat kasebut, GlaxoSmithKline.Votrient minangka inhibitor kinase sing dituduhake kanggo perawatan pasien kanthi: 1) karsinoma sel ginjel lanjut.2) sarkoma jaringan alus lanjut sing wis nampa kemoterapi sadurunge.